1-2 of 2
Ken Ogasawara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Clinical Trials & Observations
Yuliya Linhares, Cesar O. Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan C. Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ana Kostic, Min Vedal, Ken Ogasawara, Ariel Avilion, Ricardo Espinola, Brenda Yuan, Bassam Mattar
Journal: Blood Advances
Blood Adv (2024) 8 (23): 6114–6126.
https://doi.org/10.1182/bloodadvances.2024013254
Published: 2024
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Ken Ogasawara, James Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2207–2218.
https://doi.org/10.1182/bloodadvances.2021005487
Published: 2022
Includes: Supplemental data